Medicare does cover PCSK9 inhibitors, but coverage comes with strings attached. About 84% of Medicare beneficiaries have some form of coverage for Repatha, and most Part D plans list at least one PCSK9 inhibitor on their formularies. The catches: roughly 97% of Part D plans require prior authorization before they’ll pay, what you owe depends on your plan’s tier design, and manufacturer copay cards are off-limits to anyone on Medicare.1Empirical Health. PCSK9 Inhibitor Insurance Coverage
Which Part of Medicare Pays
Three PCSK9 inhibitors are on the market in the U.S.: Repatha (evolocumab), Praluent (alirocumab), and Leqvio (inclisiran). How the drug is given determines which part of Medicare covers it.
Repatha and Praluent are self-injected at home every two or four weeks. You pick them up at a pharmacy, so they fall under Medicare Part D. Every Part D plan makes its own decisions about whether to list them, what tier to place them on, and what documentation to demand.1Empirical Health. PCSK9 Inhibitor Insurance Coverage
Leqvio is different. A provider injects it in the office, with the first two doses three months apart and the rest every six months. Because it’s provider-administered, Leqvio is generally covered under Medicare Part B, the medical benefit. Medicare Advantage plans usually cover it under the medical benefit as well, though some route it through pharmacy benefits.2Leqvio. Resources and FAQs
What You’ll Actually Pay in 2026
The list prices are high but rarely what a Medicare patient pays. Repatha and Praluent carry annual list prices around $5,850, with Repatha working out to roughly $572.70 per month.3TCTMD. Pricey Inclisiran Rolling Out4Healthline. Does Medicare Cover Repatha Leqvio is $3,250 per injection, or $6,500 per year after the first year.
According to manufacturer data, about 74% of Medicare prescriptions for Repatha cost the patient $50 or less per month, and people who qualify for Medicare’s Low Income Subsidy (Extra Help) pay $12.65 or less.5Repatha. Repatha Cost Those averages hide real variation. As of 2020, all Part D plans had moved PCSK9 inhibitors off the specialty tier, but most placed them on non-preferred brand tiers where coinsurance can reach 50%. Only about a third of beneficiaries had access on a preferred brand tier.6Avalere Health. Affordable Patient Access to PCSK9 Inhibitors
The Annual Out-of-Pocket Cap
The Inflation Reduction Act put a hard ceiling on what Part D can cost you. Starting in 2025, Part D enrollees pay no more than $2,000 out of pocket for covered drugs in a calendar year. In 2026, the cap rises to $2,100.7Medical News Today. Does Medicare Cover Repatha Once you hit that number, you pay nothing for covered prescriptions the rest of the year. The old donut hole and the 5% catastrophic coinsurance are gone.8KFF. Changes to Medicare Part D in 2024 and 2025
For someone taking Repatha or Praluent, that cap is the number that matters. Your maximum annual exposure for all Part D drugs combined is $2,100 in 2026. About 11 million Part D enrollees are projected to reach the cap, saving roughly $600 on average and about $1,100 for those without other financial help.9ASPE. Impact of IRA $2,000 Cap
Spreading the Cost Across the Year
Hitting the cap can mean paying most of that $2,100 in January and February, when your deductible resets. To soften the blow, Medicare now offers the Prescription Payment Plan. It’s voluntary, all Part D plans have to offer it, and there are no fees or interest. You pay the plan in monthly installments instead of paying the full amount at the pharmacy counter. Total cost is the same; timing is smoother. Sign up by contacting your plan.10CMS. Medicare Prescription Payment Plan11Medicare. Prescription Payment Plan
Prior Authorization: What Your Plan Will Want to See
A prescription alone won’t get you a PCSK9 inhibitor. Your prescriber has to submit documentation showing you meet the plan’s medical necessity criteria. Rules vary by plan, but most look for the same three things.
First, a qualifying high-risk condition: established atherosclerotic cardiovascular disease (a prior heart attack, stroke, or peripheral artery disease), familial hypercholesterolemia confirmed by genetic testing or clinical scoring, or primary hyperlipidemia with a very high baseline LDL-C, often 190 mg/dL or above.12Anthem. PCSK9 Inhibitor Clinical Coverage Policy
Second, a documented statin trial. Plans generally want a high-intensity statin (atorvastatin 40 mg or higher, or rosuvastatin 20 mg or higher) for at least 8 to 12 weeks, or evidence of intolerance to at least two different statins. A documented contraindication such as active liver disease can also satisfy this step.12Anthem. PCSK9 Inhibitor Clinical Coverage Policy
Third, LDL cholesterol still above threshold despite treatment. Common cutoffs are 70 mg/dL or higher for patients with cardiovascular disease, or 55 mg/dL or higher for those at extreme risk. Many plans will alternatively accept documentation showing less than a 50% reduction in LDL-C after at least 90 days of compliant therapy.12Anthem. PCSK9 Inhibitor Clinical Coverage Policy
Some plans also require that the prescription come from a cardiologist, endocrinologist, or lipid specialist, or that the prescriber consult with one. A 2018 study found 42% to 71% of Medicare enrollees were in plans with some specialist prescribing restriction.13AHA Journals. PCSK9 Inhibitor Access and Utilization Management
Approval rates have improved. Amgen reports that 88% of Medicare claims for Repatha were approved as of 2025.14Repatha HCP. Coverage Information
Leqvio Usually Requires Trying Repatha First
If you’re aiming for Leqvio specifically, expect an extra hurdle. Several major Medicare Advantage insurers apply step therapy: you must try and fail Repatha (or, in some policies, Repatha or Praluent) before Leqvio is approved. Aetna’s 2026 Medicare Part B policy classifies Leqvio as “non-preferred” and Repatha as “preferred,” so Leqvio is only covered after a documented inadequate response to or intolerance of Repatha.15Aetna. Medicare Part B Drug Step Criteria: Leqvio UnitedHealthcare’s Medicare Advantage policy requires at least 12 consecutive weeks on Praluent or Repatha with minimal response, or documented intolerance, before covering Leqvio.16UnitedHealthcare. Medicare Part B Step Therapy Programs Blue Cross Blue Shield of Michigan’s Medicare Advantage plans require trial and failure of both a high-intensity statin and either Praluent or Repatha before approving Leqvio.17BCBS Michigan. MA PPO and BCN Advantage Medical Drugs Prior Authorization
Financial Help for Medicare Patients
One boundary worth knowing up front: manufacturer copay cards for Repatha and Praluent are not available to Medicare beneficiaries. Federal anti-kickback rules block their use for anyone in a government-funded program.5Repatha. Repatha Cost Leqvio’s co-pay program excludes Medicare too.2Leqvio. Resources and FAQs That’s a real disadvantage compared with commercial insurance, where those cards can drop the monthly cost to $5.
Independent charities can help fill the gap. The PAN Foundation’s Hypercholesterolemia fund provides grants of up to $3,800 per year for patients with government insurance whose household income is at or below 400% of the federal poverty level. It covers copays for Praluent, Repatha, and Leqvio.18PAN Foundation. Hypercholesterolemia Disease Fund The HealthWell Foundation runs a similar program with awards up to $2,500 for Medicare patients whose household income is between 300% and 500% of the federal poverty level, though it periodically closes to new applicants.19HealthWell Foundation. Hypercholesterolemia – Medicare Access
Regeneron runs a Patient Assistance Program that provides Praluent at no cost, but it’s limited to patients who are uninsured or have no pharmacy coverage and whose household income is at or below 300% of the federal poverty level. Medications received through the program can’t be submitted to Medicare.20Praluent. MyPraluent Patient Assistance Program Enrollment Form
If Your Plan Denies Coverage, Appeal
Denials happen, and they get overturned often. Across all services, Medicare Advantage insurers denied 7.7% of prior authorization requests in 2024, up from 6.4% the year before. More than 80% of denials that were appealed were partially or fully overturned, a pattern that has held for years.21KFF. Medicare Advantage Insurers Made Nearly 53 Million Prior Authorization Determinations in 2024
If your prior authorization is denied, ask your prescriber to file an appeal and request a coverage determination review through your plan. Before the prescription is even written, you can check whether your specific plan covers a particular PCSK9 inhibitor and estimate the cost using the Medicare Plan Finder at Medicare.gov. Bringing complete records to your prescriber’s office speeds the paperwork: the cardiovascular diagnosis or familial hypercholesterolemia confirmation, statin history with dates and doses, any specific side effects, current LDL-C labs, and whether other non-statin therapies like ezetimibe have been tried.